Gain Therapeutics, Inc.

NASDAQ:GANX

Biotechnology

Healthcare
$1.18 +3.09%

+$0.06 today

Market cap
$50.33M
Beta
0.16
P/E (TTM)
-3.6
EPS (TTM)
-$0.50
52W Low $1.41High $4.34

Volume 4.26M

Average 0.64M

GANX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Gain Therapeutics, Inc.NASDAQ: GANX

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 82.3% from a year ago

Cash & equivalents stood at $16.54M at the end of Q1 FY2026, up 82.3% from a year earlier and down 20.6% from the prior quarter. Over 3 fiscal years it compounded at +41.8% a year.

Context

  • Cash & equivalents amounted to 88.3% of total assets at the end of Q1 FY2026, up 10.2 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +82.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.54M-20.6% QoQ
Last fiscal yearDec 2025
$20.84M+100.6% YoY
Year agoMar 2025
$9.07M+82.3% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+82.3%——
1 year+100.6%——
3-year CAGR+41.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
20.84M USD
Year-over-year change
+100.6%
4-year CAGR
-13.3%

Cash & Equivalents vs competitors

How GANX compares with its peers on the latest reported figures

  • GANX's Mar 2026 cash & equivalents of $16.54M is the 7th highest of the 9 companies compared; the peer median is $94.99M.
  • Its year-over-year change of +82.3% is the 3rd highest of 9, against a peer median of +24.9%.
  • Cash & equivalents amounts to 88.3% of total assets for GANX, versus a peer median of 67.5%.
GANX Competitors Peer median
Cash & Equivalents for GANX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OSTXOS Therapies IncorporatedMar 2026$917.55M +30783.5%+1063.1%12570.5%
FBIOFortress Biotech, Inc.Mar 2026$255.84M +180.1%-23.6%71.7%
TCRXTScan Therapeutics, Inc.Mar 2026$128.06M -16.9%+8.3%63.4%
XBITXBiotech Inc.Mar 2026$115.46M -25.9%-7.2%82.6%
ADAGAdagene Inc.Dec 2025$74.52M -12.5%-19.7%95.2%
ACETAdicet Bio, Inc.Mar 2026$36.25M +28.8%-46.7%21.4%
GANXGain Therapeutics, Inc.Mar 2026$16.54M +82.3%+41.8%88.3%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$6.71M +21.0%-27.0%56.4%
NTRBNutriband Inc.Apr 2026$4.01M +35.2%+32.1%58.1%
Peer median (excluding GANX) $94.99M+24.9%-13.5%67.5%

Competitors are the stored peer set for GANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents36.88M7.31M11.79M10.39M20.84M
Short-term Investments012.83M5M00
Net Receivables195.45K103.88K242.58K765.76K802.69K
Inventory00000
Other Current Assets0640.31K0369.89K275.43K
Total Current Assets37.72M21.09M17.78M11.6M22.24M
Property, Plant & Equipment (Net)1.01M804.31K585.18K323.33K409.01K
Goodwill00000
Intangible Assets202.61K213.97K193.38K134.27K102.84K
Long-term Investments31.28K1.94M34.02K31.7K36.3K
Tax Assets(31.28K)0000
Other Non-current Assets53.39K48.32K17.89K32.11K33.7K
Total Non-current Assets1.26M3.01M830.46K521.41K581.84K
Total Assets38.99M24.1M18.61M12.12M22.82M
Account Payables560.48K1.63M1.32M946.26K825.03K
Short-term Debt103.83K108.14K118.8K110.18K100.87K
Tax Payables380107.31K48.97K00
Deferred Revenue266.5K55.18K1.12M252.21K0
Other Current Liabilities380364.11K1.38M18.49K167.89K
Total Current Liabilities2.55M4.13M4.95M3.91M3.35M
Long-term Debt590.47K495.26K449.05K328.33K300.08K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)0094.79K47.44K0
Other Non-current Liabilities329.46K157.58K307.45K443.62K390.51K
Total Non-current Liabilities1.61M1.09M1.08M872.99K901.83K
Total Liabilities4.17M5.22M6.03M4.78M4.25M
Common Stock1.19K1.19K1.62K2.71K4.21K
Retained Earnings(20.93M)(38.52M)(60.78M)(81.19M)(101.36M)
Accumulated OCI(90.65K)35.63K247.24K(247.55K)776.87K
Other Stockholders Equity00000
Minority Interest00000
Total Equity34.82M18.88M12.58M7.34M18.56M
Total Debt1.61M1.27M1.03M653.02K732.07K
Net Debt(35.27M)(6.04M)(10.77M)(9.73M)(20.11M)

Gain Therapeutics, Inc.

NASDAQ:GANX

Intrinsic Alpha fair value

Locked

Current Price

$1.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.